← boardnext 2027-09next 2028-01
IMTX
Immatics US, Inc.distress 3/10 · well-funded / low risk$9.04-1%today-24% from 52w high
Lead: Refractory Cancer
Revenue
pre-revenue
Liquidity
$454M
Runway
2.6 yrs
Shares 1y
0%
Price & events
-10.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-3.8%
1W
-8.8%
1M
-18.9%
3M
-8.8%
6M
+40.2%
1Y
-30.0%
2Y
-26.0%
5Y
-17.8%
All
Overview
- Market Cap
- $1.21B
- Volume
- 13.66K
- 52 Week Range
- $5.09 – $11.87
- Total Shares
- 134.07M
- Float Shares
- 69.59M
- Short %
- 5.73%
- % Held by Insiders
- 17.58%
- % Held by Institutions
- 79.47%
- RVOL
- 0.04x
- Beta
- 1.32
Pipeline stages · 2 programs
IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IMA203, mRNA-4203
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 1/2 | IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy | Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer | — | recruiting |
| 2028-01 Estimated 50% readout ~2028-03-16 | Phase 3 | IMA203, nivolumab plus relatlimab, lifileucel | Melanoma, Cutaneous Malignant | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 1/2 | IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product | Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer | — | recruiting |
| 2029-08 Estimated 50% readout ~2029-08-31 | Phase 1 | IMA203, mRNA-4203 | Cutaneous Melanoma, Synovial Sarcoma | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $19 (+109% upside) · 7 analysts
- 2026-05-19Chardan CapitalBuy
- 2026-04-28TD CowenBuy
- 2025-11-24Chardan CapitalBuy
- 2025-11-19MizuhoOutperform
- 2025-11-18GuggenheimBuy
- 2025-09-18GuggenheimBuy
Competitors — Refractory Cancer
Recent news
- 2026-07-19Immatics stock trades steady as pipeline and cash position frame biotech outlook - Ad-hoc-news.de
- 2026-07-17Immatics N.V. (IMTX) Stock: Cancer Treatment Pipeline Gains Momentum With Cell Therapy and Bispecific Programs - parameter.io
- 2026-07-17Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific Pipeline - Quiver Quantitative
- 2026-07-17Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - GlobeNewswire
- 2026-07-17Immatics’ three ESMO presentations span melanoma and solid tumors - Stock Titan
- 2026-07-17Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - Sahm
- 2026-07-16Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Amid Continued Pipeline Progress - Pre-Announcement Alert - dars.gov.et
- 2026-07-14(IMTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.